Esperion surges after FDA offers a shot at quick approval for LDL-lowering drug

John Carroll Shares of Esperion Therapeutics shot up more than 10% after the market closed on Monday–after the biotech tipped off investors that the FDA is not going to require ...

Mylan, Disney expand allergy-fighting partnership with new website

Carly Helfand Parents whose children have potentially life-threatening allergies now have some new resources–thanks to Mylan and Disney, which have teamed up to launch MyAllergyKingdom.com.  FiercePharma ...

UPDATED: Heard the latest Kite Pharma rumor? CEO says it ain’t so

John Carroll Kite CEO Arie Belldegrun has a simple message for investors this morning: Relax. FierceBiotech News

Proxy advisers back Mylan’s Perrigo quest as investor vote looms

Carly Helfand Mylan hopes its shareholders vote in favor of its hostile bid for Ireland's Perrigo. And it got a boost on Wednesday that may help convince them to do so at a shareholder ...

Avalanche hits the brakes on its gene therapy program after a Phase II misstep

Damian Garde Avalanche Biotechnologies, months removed from a costly Phase II dud, is calling off plans for further study of its lead gene therapy candidate, heading back to the lab ...

Novo says new U.S. plant may be best bet to offset the FX bite

Eric Palmer Novo Nordisk has forecast that currency hedging losses will leave it with an $ 850 million net loss for the year. But CEO Lars Rebien Sørensen thinks he may have ...

Art Krieg leads Checkmate as it comes out of stealth mode with $20M

Alok Saboo FierceBiotech News

NICE plots takeover of England’s Cancer Drugs Fund

Emily Wasserman England's Cancer Drugs Fund has been dealing with budget overruns and backlash from drugmakers and patients unhappy with the fund's decision to ax certain meds ...

CRO giant WuXi is going private in a $3.3B deal

Damian Garde WuXi PharmaTech, China's largest CRO, agreed to a $ 3.3 billion buyout deal that would take it off of Wall Street and into the hands of some private investors. FierceBiotech ...

Shire raise its $30B Baxalta bid? It’s going to need some details first

Carly Helfand Earlier this week, Baxalta CEO Ludwig Hantson called Shire's $ 30 billion bid for his company a "lowball" offer, urging shareholders instead to look to ...

Takeda Actos settlement seems shaky as plaintiffs give it the sniff test

Eric Palmer Takeda's new CEO, Christophe Weber, thought the Japanese drugmaker had freed itself of the drag from thousands of lawsuits tied to cancer risks from its diabetes drug ...

Novo Nordisk ties the R&D knot with Genmab, and they’re not focused on cancer

John Carroll Novo Nordisk is jumping on Genmab's antibody development platform in search of two new drug programs–and this time the Danish biotech company will not be focused ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS